Detection of serum antimüllerian hormone in women approaching menopause using sensitive antimüllerian hormone enzyme-linked immunosorbent assays

Robertson, David; Kumar, Ajay; Kalra, Bhanu; Shah, Sneha; Pruysers, Enid; Brink, Heidi Vanden; Chizen, Donna R.; Visser, Jenny A.; Themmen, Axel P. N.; Baerwald, Angela

doi:10.1097/gme.0000000000000244

Cited by 46 publications

(39 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, AMH level exhibits increasing intracycle variation as women approach menopause; AMH level may have been detectable in this group of still‐cycling women if measured at a different time point during a cycle when antral follicle count was higher (Robertson et al, ). AMH level has been shown to be more tightly correlated with antral follicle count in younger women, but the relationship is less consistent in late reproductive age, which might account for continued reports of menstrual bleeding in the absence of a detectable AMH level (Robertson et al, ; Vanden Brink et al, ).…”

Section: Discussionmentioning

confidence: 99%

Variation in levels of AMH among Maya and non‐Maya women in Campeche, Mexico

Kyweluk

Sievert

Gómez

et al. 2018

American J Phys Anthropol

View full text Add to dashboard Cite

Increasing age and progression through the menopausal transition were both associated with declining levels of AMH. The association between Maya ethnicity and a lower likelihood of detecting AMH is consistent with the early ages at menopause reported in previous studies. We considered a rapid life history model as an explanatory framework, and suggest, from an ecological perspective, that future research should consider measures of developmental stress that may compromise ovarian reserves.

show abstract

Section: Discussionmentioning

confidence: 99%

Variation in levels of AMH among Maya and non‐Maya women in Campeche, Mexico

Kyweluk

Sievert

Gómez

et al. 2018

American J Phys Anthropol

View full text Add to dashboard Cite

show abstract

“…Somehow contradictory, a larger study including more than 3000 women shows that one‐third of the intracyclic variation is due to aging and it has been shown that the variation is more pronounced in older women .…”

Section: Methodsmentioning

confidence: 99%

“…Somehow contradictory, a larger study including more than 3000 women shows that one-third of the intracyclic variation is due to aging (51) and it has been shown that ª 2018 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 97 (2018) 1105-1113 the variation is more pronounced in older women (49,52).…”

Section: Amh and The Chance Of Achieving Pregnancymentioning

confidence: 99%

The use of anti‐Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and ‐counseling

Pilsgaard

Grynnerup

Løssl

et al. 2018

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Ovarian reserve can be determined by serum anti-Müllerian hormone (AMH) level and/or antral follicle count before controlled ovarian stimulation. The aim of controlled ovarian stimulation is to achieve an appropriate number of mature follicles and avoid complications such as ovarian hyperstimulation syndrome. Measurement of the ovarian reserve is useful for clinicians as it predicts the ovarian response to controlled ovarian stimulation. Further, it assists in giving the patient realistic expectations regarding the treatment. By determining the ovarian reserve, the most appropriate stimulation protocol and gonadotropin dose can be chosen specifically for each woman enabling so-called "individualized treatment" in line with the personalized treatment concept. Many benefits come with using AMH as a biomarker for ovarian reserve; the hormone is considered fairly cycle independent apart from a small decrease in the late follicular phase and there is no inter-observer variance. However, the use of AMH also has limitations; since the implementation of AMH in fertility treatment several AMH assays have been developed. This has made direct comparisons of AMH serum levels complicated. Currently, no international standardized assays exist. AMH is a valid predictor of the ovarian response to controlled ovarian stimulation and to some extent the chance of pregnancy in relation to assisted reproductive technology, but AMH is less optimal in prediction of spontaneous pregnancy and live birth after assisted reproductive technology. Accordingly, AMH can be used to optimize gonadotropin stimulation in fertility treatment, but is not recommended as a screening tool in the general population.

show abstract

“…Last, the recent emergence of high-sensitive assays, such as the picoAMH assay used in this study, has enabled measurement of AMH in women in and after the menopausal transition. 20,44 However, the relevance of AMH detection and variation in low ranges still remains a subject of speculation and requires further research.…”

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women

et al. 2017

View full text Add to dashboard Cite

BACKGROUND:Earlier age at menopause is widely considered to be associated with an increased risk of cardiovascular disease. However, the underlying mechanisms of this relationship remain undetermined. Indications suggest that anti-Müllerian hormone (AMH), an ovarian reserve marker, plays a physiological role outside of the reproductive system. Therefore, we investigated whether longitudinal AMH decline trajectories are associated with an increased risk of cardiovascular disease (CVD) occurrence. METHODS:This study included 3108 female participants between 20 and 60 years of age at baseline of the population-based Doetinchem Cohort. Participants completed ≥1 of 5 consecutive quinquennial visits between 1987 and 2010, resulting in a total follow-up time of 20 years. AMH was measured in 8507 stored plasma samples. Information on total CVD, stroke, and coronary heart disease was obtained through a hospital discharge registry linkage. The association of AMH trajectories with CVD was quantified with joint modeling, with adjustment for age, smoking, oral contraceptive use, body mass index, menopausal status, postmenopausal hormone therapy use, diastolic blood pressure, total cholesterol, highdensity lipoprotein cholesterol, and glucose levels. RESULTS:By the end of follow-up, 8.2% of the women had suffered from CVD, 4.9% had suffered from coronary heart disease, and 2.6% had experienced a stroke. After adjustment, each ng/mL lower log AMH level was associated with a 21% higher risk of CVD (hazard ratio, 1.21; 95% confidence interval, 1.07-1.36) and a 26% higher risk of coronary heart disease (hazard ratio, 1.25; 95% confidence interval, 1.08-1.46). Each additional ng/mL/year decrease of log AMH was associated with a significantly higher risk of CVD (hazard ratio, 1.46; 95% confidence interval, 1.14-1.87) and coronary heart disease (hazard ratio, 1.56; 95% confidence interval, 1.15-2.12). No association between AMH and stroke was found. CONCLUSIONS:These results indicate that AMH trajectories in women are independently associated with CVD risk. Therefore, we postulate that the decline of circulating AMH levels may be part of the pathophysiology of the increased cardiovascular risk of earlier menopause. Confirmation of this association and elucidation of its underlying mechanisms are needed to place these results in a clinical perspective.

show abstract

Detection of serum antimüllerian hormone in women approaching menopause using sensitive antimüllerian hormone enzyme-linked immunosorbent assays

Abstract: The new 24/32 and 24/37 AMH ELISAs have the sensitivity to monitor ovarian follicle profiles in late reproductive age.

Cited by 46 publications

References 29 publications

Variation in levels of AMH among Maya and non‐Maya women in Campeche, Mexico

Variation in levels of AMH among Maya and non‐Maya women in Campeche, Mexico

The use of anti‐Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and ‐counseling

Anti-Müllerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women

Contact Info

Product

Resources

About